Aliases & Classifications for Skin Atrophy

MalaCards integrated aliases for Skin Atrophy:

Name: Skin Atrophy 12 14
Atrophic Condition of Skin 12 69
Atrophy - Skin 12
Atrophoderma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2733
ICD10 33 L90 L90.9
NCIt 47 C35163
UMLS 69 C0151514

Summaries for Skin Atrophy

MalaCards based summary : Skin Atrophy, also known as atrophic condition of skin, is related to atrophoderma of pierini and pasini and atrophoderma vermiculata. An important gene associated with Skin Atrophy is FERMT1 (Fermitin Family Member 1), and among its related pathways/superpathways are Adhesion and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Tacrolimus and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and liver, and related phenotypes are cellular and growth/size/body region

Wikipedia : 72 Atrophoderma refers to conditions involving skin... more...

Related Diseases for Skin Atrophy

Graphical network of the top 20 diseases related to Skin Atrophy:



Diseases related to Skin Atrophy

Symptoms & Phenotypes for Skin Atrophy

MGI Mouse Phenotypes related to Skin Atrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.87 CD44 FBLIM1 FERMT1 GJA1 KL SAT1
2 growth/size/body region MP:0005378 9.86 CD44 EBP FERMT1 GJA1 HBEGF KL
3 integument MP:0010771 9.63 KL CD44 EBP FERMT1 GJA1 HBEGF
4 respiratory system MP:0005388 9.35 CD44 GJA1 HBEGF KL TCOF1
5 skeleton MP:0005390 9.1 CD44 FBLIM1 GJA1 HBEGF KL TCOF1

Drugs & Therapeutics for Skin Atrophy

Drugs for Skin Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
3
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
4
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
5
Hydroquinone Approved Phase 4 123-31-9 785
6
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
7 Racepinephrine Approved Phase 4
8
Goserelin Approved Phase 4 65807-02-5 47725 5311128
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
10
Cysteamine Approved, Investigational Phase 4 60-23-1 6058
11
Adapalene Approved Phase 4 106685-40-9 60164
12
Benzoyl peroxide Approved Phase 4 94-36-0 7187
13
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
14
Ornithine Approved, Nutraceutical Phase 4,Phase 1 70-26-8, 3184-13-2 6262 389
15
Clobetasol Investigational Phase 4,Phase 3,Phase 2,Phase 1 25122-46-7, 25122-41-2 32798 5311051
16 Anti-Allergic Agents Phase 4,Phase 1
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Calcineurin Inhibitors Phase 4
19 Dermatologic Agents Phase 4,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
21 mometasone furoate Phase 4,Phase 1 83919-23-7
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
23 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Protective Agents Phase 4,Phase 2,Phase 1
28 triamcinolone acetonide Phase 4,Phase 2
29 Triamcinolone diacetate Phase 4,Phase 2
30 Triamcinolone hexacetonide Phase 4,Phase 2
31 Analgesics Phase 4
32 Analgesics, Non-Narcotic Phase 4
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4
34 Antirheumatic Agents Phase 4,Phase 2
35 Antioxidants Phase 4
36 Keratolytic Agents Phase 4
37 Radiation-Protective Agents Phase 4
38 Anti-Asthmatic Agents Phase 4,Phase 1
39 Autonomic Agents Phase 4
40 Bronchodilator Agents Phase 4
41 Epinephryl borate Phase 4
42
Fluticasone Phase 4 90566-53-3, 80474-14-2 62924 22833648
43 Respiratory System Agents Phase 4,Phase 1
44 EMLA Phase 4
45 Emollients Phase 4,Phase 1,Phase 2
46 Anti-Infective Agents Phase 4,Phase 1,Phase 2
47 Antiparasitic Agents Phase 4
48 Antiprotozoal Agents Phase 4
49 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1
50 Antidotes Phase 4

Interventional clinical trials:

(show top 50) (show all 78)

id Name Status NCT ID Phase Drugs
1 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
2 Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
3 Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Completed NCT00469183 Phase 4 Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
4 Cutivate Lotion HPA Axis Pediatric Study Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
5 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
6 Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis Completed NCT01202149 Phase 4
7 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
8 Evaluation of Eflornithine on Facial and Forearm Skin Completed NCT00152048 Phase 4 Eflornithine hydrochloride
9 A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric S Completed NCT01915914 Phase 4 Fluticasone propionate
10 Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy Completed NCT00851461 Phase 4 Goserelin
11 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis Completed NCT00028262 Phase 4 Cystagon
12 Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis Completed NCT01111123 Phase 4 Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%);Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
13 Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars Active, not recruiting NCT02735421 Phase 4 Adapalene 0.3% / BPO 2.5% gel;Vehicle gel
14 Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids Unknown status NCT00709579 Phase 3 RV3391A;Placebo
15 Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis Completed NCT00658788 Phase 3 clobetasol propionate spray 0.05%;calcitriol ointment
16 S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults Completed NCT00110747 Phase 3 S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%);Placebo Peel
17 Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty Completed NCT01096524 Phase 3
18 The Effect of Pre-operative Electrical Stimulation on Peripheral Nerve Regeneration. Recruiting NCT03205124 Phase 2, Phase 3
19 Modafinil to Treat Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3 Modafinil
20 Efficacy of TCA Effect on Varicella Atrophic Scars Unknown status NCT00422539 Phase 2 70% trichloroacetic acid
21 Adipose Derived Stem Cells in Facial Fat Grafting Unknown status NCT02526576 Phase 2
22 Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo Unknown status NCT01766609 Phase 2 Triamcinolone Acetonide
23 Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test Completed NCT02111499 Phase 1, Phase 2 LAS41004-IMP1;LAS41004 IMP2;LAS41004 IMP3;LAS41004 IMP4;LAS41004 IMP6;LAS41004 IMP5
24 Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment Completed NCT01553773 Phase 2 isoflavone;Estradiol
25 Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy Completed NCT01407471 Phase 2 Clobetasol + Spironolactone;Clobetasol + Placebo;Placebo + Spironolactone;Placebo + Placebo
26 Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA) Completed NCT00303446 Phase 2 Dutasteride;Placebo
27 Effect of Electrical Muscle Stimulation in Critically Ill Patients Completed NCT01637467 Phase 1, Phase 2
28 Fractional Resurfacing Device for Treatment of Acne Scarring Completed NCT00585286 Phase 1, Phase 2
29 The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus Completed NCT02106468 Phase 2 Prednisone tablet 5mg;Omega-3 soft capsules 1000 mg
30 Novel Compositions for Treating or Preventing Dermal Disorders Recruiting NCT03103893 Phase 1, Phase 2 Rapamycin
31 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Recruiting NCT01086540 Phase 2
32 Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study Not yet recruiting NCT02810015 Phase 2 Botulinum Toxin Type A
33 Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. Suspended NCT01122342 Phase 1, Phase 2 Testosterone propionate
34 Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Unknown status NCT02034786 Phase 1
35 A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin Completed NCT02355639 Phase 1 Clobetasol propionate 0.05 % ointment;Betamethasone dipropionate 0.064 % ointment;Petrolatum ointment
36 A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin Completed NCT02392130 Phase 1 Clobetasol propionate 0.05% ointment;LEO 130852A gel 1%;LEO 130852A placebo gel
37 A Study Assessing GW870086's Potential to Cause Skin Thinning Completed NCT01381445 Phase 1 GW870086 0.2%;GW870086 2%;Clobetasol Propionate;Placebo
38 Gene Therapy for Gyrate Atrophy Completed NCT00001735 Phase 1
39 Phase I Study of Topical CRx-191 in Normal Healthy Volunteers Completed NCT00544687 Phase 1 CRx-191;mometasone furoate;nortriptyline HCl;Karison® Creme;Vehicle
40 BION Active Seating for Pressure Ulcer Prevention Completed NCT00628602 Phase 1
41 Fat Grafting for Pedal Fat Pad Atrophy in Diabetics Active, not recruiting NCT02074683 Phase 1
42 The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata Unknown status NCT00999869 Botulinum toxin type A;Triamcinolone acetonide
43 Treatment of Atrophic Acne Scars With a Fractional CO2 Laser at 1 Versus 3 Months Intervals Unknown status NCT01773343
44 Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging Completed NCT00974480 Tretinoin (Rejuva-A)
45 Gyrate Atrophy of the Choroid and Retina Completed NCT00001166
46 Fat Grafting for Pedal Fat Pad Atrophy Completed NCT01796808 Local anesthetic
47 Microneedling Plus the Universal Peel For Acne Scarring Completed NCT02174393 Universal Peel;Post-Microneedling Skin Care;Post-Universal Peel Skin Care
48 Effectiveness of the Kinesio Taping® in Muscle Activation Completed NCT01991171
49 Serial Daily Diaphragm Ultrasounds in Ventilated Patients Completed NCT02174029
50 Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata Completed NCT01797432 Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)

Search NIH Clinical Center for Skin Atrophy

Genetic Tests for Skin Atrophy

Anatomical Context for Skin Atrophy

MalaCards organs/tissues related to Skin Atrophy:

39
Skin, Testes, Liver, Bone, Retina, Thyroid, Tongue

Publications for Skin Atrophy

Articles related to Skin Atrophy:

(show all 50)
id Title Authors Year
1
Intralesional Treatment With 5-Fluorouracil and Steroid Improves Allergic Contact Dermatitis Without Causing Skin Atrophy and Rebound Lesions. ( 28338541 )
2017
2
Annular Plaques With Skin Atrophy in a Young Patient. ( 28122082 )
2017
3
Surgical Answer to Intralesional Steroid-Induced Skin Atrophy. ( 27870650 )
2016
4
Acral skin atrophy in an infant: an early clue to Kindler syndrome diagnosis. ( 25764106 )
2015
5
Topical corticosteroid-induced skin atrophy: a comprehensive review. ( 25862024 )
2015
6
Resveratrol Derivative-Rich Melinjo Seed Extract Attenuates Skin Atrophy in Sod1-Deficient Mice. ( 26180586 )
2015
7
Palladium and Platinum Nanoparticles Attenuate Aging-Like Skin Atrophy via Antioxidant Activity in Mice. ( 25333617 )
2014
8
Collagen peptide and vitamin C additively attenuate age-related skin atrophy in Sod1-deficient mice. ( 25229861 )
2014
9
Hyalurosome gene regulation and dose-dependent restoration of skin atrophy by retinaldehyde and defined-size hyaluronate fragments in dermatoporosis. ( 25138066 )
2014
10
Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. ( 25027750 )
2014
11
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 24488534 )
2014
12
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 23242470 )
2013
13
Vulvar skin atrophy induced by topical glucocorticoids. ( 22594868 )
2012
14
Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. ( 22512680 )
2012
15
Linear skin atrophy preceding calcinosis cutis in pseudo-pseudohypoparathyroidism. ( 22299648 )
2012
16
Fluorescence spectroscopy as a tool to detect and evaluate glucocorticoid-induced skin atrophy. ( 22249456 )
2012
17
Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. ( 22110776 )
2011
18
Evaluation of skin atrophy associated with linear atrophoderma of Moulin by ultrasound imaging. ( 21679833 )
2011
19
Shortened treatment duration of glucocorticoid-induced skin atrophy in rats. ( 21824195 )
2011
20
Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy. ( 20051715 )
2010
21
A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. ( 19755910 )
2009
22
Skin atrophy in cytoplasmic SOD-deficient mice and its complete recovery using a vitamin C derivative. ( 19289104 )
2009
23
In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle. ( 18246695 )
2008
24
Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. ( 19057668 )
2008
25
Glucocorticoid therapy-induced skin atrophy. ( 16689857 )
2006
26
Action of topical thyroid hormone analogues on glucocorticoid-induced skin atrophy in mice. ( 16571090 )
2006
27
Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans. ( 17123343 )
2006
28
Hyaluronate fragments reverse skin atrophy by a CD44-dependent mechanism. ( 17177600 )
2006
29
Skin atrophy caused by thiocolchicoside injections. ( 17184273 )
2006
30
Topical tacrolimus and pimecrolimus are not associated with skin atrophy. ( 11903264 )
2002
31
Dose-response effects of tri-iodothyroacetic acid (Triac) and other thyroid hormone analogues on glucocorticoid-induced skin atrophy in the haired mouse. ( 12353707 )
2002
32
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. ( 11260007 )
2001
33
Eyelid skin atrophy associated with chronic usage of ophthalmic steroid ointment, and its successful treatment with the Versapulse laser. ( 11702982 )
2001
34
The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. ( 9990383 )
1998
35
Skin atrophy of the eyelid induced by topical ophthalmic corticosteroids. ( 9686858 )
1998
36
Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. ( 9553910 )
1998
37
Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. ( 7894098 )
1995
38
In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin. ( 8106754 )
1994
39
Combination of a dual 5-lipoxygenase/cyclooxygenase inhibitor with a glucocorticoid results in synergistic topical antiinflammatory activity without inducing skin atrophy. ( 8225561 )
1993
40
Morphometric computerized analysis as a method to assess skin atrophy caused by corticosteroids. ( 8489771 )
1993
41
0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. ( 1618247 )
1992
42
Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. ( 2768567 )
1989
43
Remote skin atrophy caused by topical steroids. ( 21253139 )
1988
44
Linear skin atrophy, scarring alopecia, anonychia, and tongue lesion: a "new" syndrome? ( 4040704 )
1985
45
Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo. ( 3888708 )
1985
46
Infection and prematurity as the cause of linear skin atrophy, alopecia, anonychia, and tongue lesions? ( 3901928 )
1985
47
A study of potential skin atrophy following topical application of weak corticosteroids. ( 7261664 )
1981
48
Comparative evaluation of skin atrophy in man induced by topical corticoids. ( 154921 )
1979
49
Periarticular perilymphatic skin atrophy after intra-articular corticosteroid injections. ( 671670 )
1978
50
Mechanism of local skin atrophy caused by intradermally injected corticosteroids. ( 133836 )
1976

Variations for Skin Atrophy

Expression for Skin Atrophy

Search GEO for disease gene expression data for Skin Atrophy.

Pathways for Skin Atrophy

GO Terms for Skin Atrophy

Cellular components related to Skin Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.35 CD44 EBP GJA1 HBEGF KL
2 focal adhesion GO:0005925 8.92 CD44 FBLIM1 FERMT1 GJA1

Molecular functions related to Skin Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.62 HBEGF KL

Sources for Skin Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....